Keymed Biosciences Inc. (HKG:2162)
Hong Kong · Delayed Price · Currency is HKD 57.50
+1.60 (2.86%)
Jun 18, 2026, 4:08 PM HKT
Keymed Biosciences Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, Keymed Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $92.95. The average 1-year stock price forecast is 61.65% higher than the current stock price, while the lowest is $85.04 (+47.90%) and the highest is $103.52 (+80.03%).
Price Target: $92.95 (+61.65%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Keymed Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 7 | 7 | 6 | 6 | 6 |
| Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 10 | 10 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Shenwan Hongyuan No rating | Shenwan Hongyuan | Buy Maintains $89.47 | Buy | Maintains | $89.47 | +55.60% | May 28, 2026 |
Unknown Analyst Morgan Stanley No rating | Morgan Stanley | Buy Maintains $97.00 | Buy | Maintains | $97.00 | +68.70% | May 28, 2026 |
Unknown Analyst KeyBanc No rating | KeyBanc | Buy Maintains $87.31 | Buy | Maintains | $87.31 | +51.84% | Apr 4, 2026 |
Unknown Analyst Huatai Securities No rating | Huatai Securities | Buy Maintains $91.08 → $91.13 | Buy | Maintains | $91.08 → $91.13 | +58.49% | Mar 30, 2026 |
Unknown Analyst CLSA No rating | CLSA | Buy Maintains $78.00 | Buy | Maintains | $78.00 | +35.65% | Mar 24, 2026 |
Financial Forecast
Revenue This Year
2.41B
from 716.31M
Increased by 235.81%
Revenue Next Year
2.16B
from 2.41B
Decreased by -10.38%
EPS This Year
2.70
from -1.81
EPS Next Year
0.56
from 2.70
Decreased by -79.05%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 2.7B | ||
| Avg | 2.4B | ||
| Low | 1.6B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 282.9% | ||
| Avg | 235.8% | ||
| Low | 123.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 2.70 | ||
| Avg | 2.70 | ||
| Low | 2.69 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |